You have 9 free searches left this month | for more free features.

AZD5305; HRRm; non-HRRm; mCSPC; Prostate Cancer

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Metastatic Castration-Sensitive Prostate Cancer Trial in Worldwide (AZD5305, Placebo, Abiraterone Acetate)

Not yet recruiting
  • Metastatic Castration-Sensitive Prostate Cancer
  • Tucson, Arizona
  • +192 more
Nov 6, 2023

Ovarian Cancer, Breast Cancer, Pancreatic Cancer Trial in Worldwide (AZD5305, Paclitaxel, Carboplatin)

Recruiting
  • Ovarian Cancer
  • +12 more
  • San Francisco, California
  • +44 more
Jul 12, 2022

Prostate Cancer Trial in Worldwide (AZD5305, Darolutamide, No Treatment)

Not yet recruiting
  • Prostate Cancer
  • Melbourne, Australia
  • +7 more
Jul 3, 2023

Advanced Solid Tumors Trial in Worldwide (Olaparib)

Recruiting
  • Advanced Solid Neoplasms
  • Tucson, Arizona
  • +128 more
Aug 18, 2022

Metastatic Prostate Cancer Trial in Australia, United Kingdom (AZD5305, Enzalutamide, Abiraterone Acetate)

Recruiting
  • Metastatic Prostate Cancer
  • San Diego, California
  • +25 more
Jan 10, 2023

Patterns and Associated Clinical Outcomes in Metastatic

Completed
  • Metastatic Castration-resistant Prostates Cancer
    • Valledupar, Colombia
    • +29 more
    Jan 16, 2023

    Learn About Novel Hormonal Therapies for Metastatic

    Not yet recruiting
    • Prostatic Neoplasms
    • Novel hormonal therapy
    • New York, New York
      Pfizer Inc
    Nov 21, 2023

    Learn About Novel Hormonal Therapies in People With Metastatic

    Not yet recruiting
    • Prostatic Neoplasms
    • Novel hormonal therapy
    • New York, New York
      Pfizer Inc
    Oct 2, 2023

    Metastatic Castrate-sensitive Prostate Cancer Trial in Germany, United States (Apalutamide, Androgen-deprivation Therapy (ADT))

    Not yet recruiting
    • Metastatic Castrate-sensitive Prostate Cancer
    • Lakewood, Colorado
    • +5 more
    May 23, 2023

    Metastatic Triple Negative Breast Cancer Trial in Worldwide (Olaparib Continuous (28-Day cycle) 300 mg BD., Ceralasertib 160 mg

    Active, not recruiting
    • Metastatic Triple Negative Breast Cancer
    • Olaparib Continuous (28-Day cycle) 300 mg BD.
    • +2 more
    • Birmingham, Alabama
    • +140 more
    Nov 17, 2022

    Metastatic Castrate Sensitive Prostate Cancer Trial in Worldwide (Niraparib, Abiraterone acetate (AA), Prednisone)

    Recruiting
    • Metastatic Castrate Sensitive Prostate Cancer
    • Homewood, Alabama
    • +439 more
    Jan 17, 2023

    Called AWARENESS Using Data From Alberta to Observe Treatment

    Active, not recruiting
    • Metastatic Castration-sensitive Prostate Cancer
    • ADT (Eligard®*) with or without treatment intensification
    • Multiple Locations, Alberta, Canada
    • +1 more
    Aug 1, 2022

    Determination of Prevalence and Features of HRRm mCRPC (ADAM)

    Active, not recruiting
    • HRRm mCRPC
      • Barnaul, Altai Krai, Russian Federation
      • +12 more
      Apr 26, 2022

      Cancer Of Prostate, Prostate Tumors Trial run by the National Cancer Institute (NCI) (ADT, Prednisone, M7824)

      Recruiting
      • Cancer Of Prostate
      • Prostate Neoplasms
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jul 6, 2022

      NSCLC NSCLC Trial in Worldwide (Durvalumab, Placebo for Olaparib, Olaparib)

      Active, not recruiting
      • Non-small Cell Lung Cancer NSCLC
      • Bonita Springs, Florida
      • +67 more
      Nov 15, 2022

      Metastatic Prostate Cancer Trial (Darolutamide, Radium-223)

      Not yet recruiting
      • Metastatic Prostate Cancer
      • (no location specified)
      Mar 6, 2023

      Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer Trial in Worldwide (Datopotamab deruxtecan

      Not yet recruiting
      • Endometrial Cancer
      • +4 more
      • Datopotamab deruxtecan (Dato-DXd)
      • +8 more
      • Los Angeles, California
      • +52 more
      Aug 3, 2022

      Advanced Solid Malignancies Trial in Tbilisi, Chisinau, Cluj-Napoca (AZD5305, Itraconazole)

      Recruiting
      • Advanced Solid Malignancies
      • Tbilisi, Georgia
      • +2 more
      Jan 20, 2023

      Prostate Cancer Trial in Boston (Precision screening intervention, Usual care)

      Not yet recruiting
      • Prostate Cancer
      • Precision screening intervention
      • Usual care
      • Boston, Massachusetts
        VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain,
      Jun 21, 2023

      Prostate Cancer Trial in Worldwide (talazoparib plus enzalutamide, Placebo plus enzalutamide)

      Recruiting
      • Prostate Cancer
      • talazoparib plus enzalutamide
      • Placebo plus enzalutamide
      • Birmingham, Alabama
      • +306 more
      Jan 18, 2023

      HER2 Expression and Clinical Pathological Characteristics in

      Recruiting
      • HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer
      • Collect HER2 expression in prostate cancer patients
      • Jinan, Shandong, China
        Qilu hospital
      Nov 17, 2023

      Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8 Trial in Kansas City

      Not yet recruiting
      • Stage IIC Prostate Cancer AJCC v8
      • +2 more
      • Biospecimen Collection
      • +9 more
      • Kansas City, Kansas
        University of Kansas Cancer Center
      Nov 3, 2023

      Prostate Cancer Trial in Cincinnati (Apalutamide Oral Product, Androgen Deprivation Therapy (ADT), Focal Therapy)

      Not yet recruiting
      • Prostate Cancer
      • Apalutamide Oral Product
      • +2 more
      • Cincinnati, Ohio
        University of Cincinnati Medical Center
      Mar 27, 2023

      Glioblastoma, Squamous Cell Carcinoma, Hodgkin Lymphoma Trial (AVM0703, Hydrocortisone, Proton pump inhibitor)

      Available
      • Glioblastoma
      • +13 more
      • (no location specified)
      Jul 26, 2023

      Prostate Cancer Trial in Philadelphia (Daily adaptive SBRT with urethral sparing)

      Not yet recruiting
      • Prostate Cancer
      • Daily adaptive SBRT with urethral sparing
      • Philadelphia, Pennsylvania
        Fox Chase Cancer Center
      Mar 26, 2023